Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

CANUT Junior : Assessment of Sensory Abilities and Eating Behavior in Pediatric Oncology: a Feasibility Study (CANUT Junior)

2 juin 2026 mis à jour par: Centre Leon Berard

Cancer treatments in children are very intense and often cause side effects such as nausea, vomiting, loss of appetite, and changes in taste and smell. These sensory alterations can impact eating habits, but they are still poorly understood in children. The study aims to assess whether it is feasible to measure these sensory changes (taste, smell, salivation, and food preferences) in children and adolescents undergoing cancer treatment.

This study is a feasibility study with 30 patients aged 7 to 17 years, treated at the Pediatric Hematology and Oncology Institute (IHOPE) in Lyon. Sensory tests and questionnaires to evaluate the perceptions, oral health, eating habits, nutritional status, and quality of life are used.

The inclusion was initially planned at diagnosis, before any administration of chemotherapy. However, the study quickly encountered a recruitment problem due to the emotional impact and medical burden of this initial period of care (study offered to 11 families over a period of 5 months, 3 patients included). An amendment to the protocol was therefore made to be able to modify the inclusion period after the completion of chemotherapy. This modification was implemented on May 15, 2025, and allowed the inclusion of two new patients, making a total of 5 patients. Of these 5 patients, two completed all the tests during V0 and V1, two completed V0 but not V1, one did not complete any of the visits.

This feasibility phase will help determine whether the tools are suitable and well accepted. The results will be used to design a larger study aimed at better understanding how taste and smell alterations influence the eating behaviors of young patients during cancer treatment. Recruitment will continue for six more months in order to reach the target number of participants.

Aperçu de l'étude

Statut

Recrutement

Intervention / Traitement

Description détaillée

Today, the chances of survival among children and adolescents who have been diagnosed with cancer are 80%, particularly due to early diagnosis and access to appropriate care. Although multimodal care strategies have improved the survival rate in pediatric patients, highly toxic treatments cause various short- and long-term side effects such as nausea, vomiting, loss of appetite, and alterations in taste perception. These side effects affect the comfort and quality of life of patients and expose them to a high risk of malnutrition. Sensory alterations related to smell, taste and texture reduce appetite and pleasure in eating, thus reducing food intake. More than 45% of children and adolescents treated for cancer suffer from malnutrition, which impacts their immune function, their response to treatments, their quality of life and even the costs of care. The consequences of sensory alterations on behaviors, preferences and eating habits are still little studied in children and adolescents treated for cancer. Similarly, olfactory and somesthetic capacities are very little explored in these patients. Only few studies are available in this area in pediatrics, and no studies take into account texture perception, which is essential for food acceptance.

This study is a feasibility study aimed at exploring the tools for measuring sensory alterations. It aims to evaluate taste and olfactory capacities, as well as food preferences in terms of textures among children. The study is a single-arm intervention. The study will include 30 patients between 7 and 17 years old, newly diagnosed with oncological or hematological malignancies, treated at IHOPE (Institute of Hematology and Pediatric Oncology) in Lyon, until today 3 patients have been included. The protocol had to undergo a second session in the Ethics County for changes to the recruitment process on May 7, 2025, with the aim of having more inclusions of participants. The change consists of doing the tests before the second chemotherapy cycle instead of the first cycle since patients have a lot of procedures to do in hospital management and they did not agree to participate in the study. The measures that are taken are, olfactory and gustatory capacities, measurement of salivary quantity and quality, preference and acceptance of textures. The state of oral health, dietary habits and food consumption with questionnaires are also assessed. Measurements of weight, height and BMI are taken, and nutritional status is assessed. The Easy Assessment Score of Ingesta is also used for an early diagnosis of the risk of malnutrition or undernutrition and finally the quality of life with the help of a questionnaire.

Type d'étude

Interventionnel

Inscription (Estimé)

30

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Lyon, France, 69008
        • Recrutement
        • Institut d'Hématologie et d'Oncologie Pédiatrique
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Patients treated at a pediatric oncology-hematology center, with an initial diagnosis of a solid or hematological tumor, aged 7 to 17 years inclusive.
  • Patients with functional oral feeding
  • Parent/guardian who has signed the informed consent form and patient who has not expressed refusal
  • Patients affiliated with the social security system
  • French-speaking patients
  • Validated indication for systematic oncological treatment

Exclusion Criteria:

  • Individuals with a known food allergy/intolerance to the prototypes being studied (does not apply to patients on a protected diet)
  • Individuals who have undergone surgery on the tongue
  • Patients for whom other types of cancer treatment are planned during the study period (e.g., radiation therapy)
  • Patients with dental conditions
  • Patients who have relapsed

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Experimental arm
The measures that are taken are, olfactory and gustatory capacities, measurement of salivary quantity and quality, preference and acceptance of textures. We also assess the state of oral health, dietary habits and food consumption with questionnaires. Measurements of weight, height and BMI are taken, and nutritional status is assessed. The Easy Assessment Score of Ingesta is also used for an early diagnosis of the risk of malnutrition or undernutrition and finally the quality of life with the help of a questionnaire.
The measures that are taken are, olfactory and gustatory capacities, measurement of salivary quantity and quality, preference and acceptance of textures. We also assess the state of oral health, dietary habits and food consumption with questionnaires. Measurements of weight, height and BMI are taken, and nutritional status is assessed. The Easy Assessment Score of Ingesta is also used for an early diagnosis of the risk of malnutrition or undernutrition and finally the quality of life with the help of a questionnaire.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To determine the feasibility of testing olfactory, gustatory, and salivary function in children aged 7 to 17 years undergoing chemotherapy.
Délai: T0 : first day of the second cycle of chemotherapy; T1 : 1 month after T0

Completion rate: proportion of patients who complete all of the following tests in full at both measurement times.

The tests will be considered feasible if at least 60% of patients complete all of the tests

T0 : first day of the second cycle of chemotherapy; T1 : 1 month after T0

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Correlation between impaired olfactory ability / impaired taste ability and: Sensitivity to texture /Texture preference / Food preferences and habits / Salivary function / Caloric intake / Nutritional status / Quality of life
Délai: T0 : first day of the second cycle of chemotherapy; T1 : 1 month after T0

evaluating the rate of patients presenting olfactory impairment (assessed by the Sniffin Sticks test) or taste impairment (assessed using taste strips) who are also presenting :

  • taste impairment, using the Taste Alteration Scale for Children with Cancer Receiving Chemotherapy questionnaires and the Gustonco questionnaire.
  • a modification of sensitivity to texture, measured on a 7-point smiley scale using food samples
  • a modification of food texture preference assessed using a questionnaire based on pictographic drawings.
  • a modification of food preferences and habits assessed using the Behavioral Pediatrics Feeding Assessment Scale
  • a modification of salivary function measured using a Saliva-check BUFFER kit.

The daily calorie intake of every patient will be assessed using a 24-hour food diary, the nutritional status (weight in kg, height in cm, body mass index (BMI)and the quality of life will be assessed using the PedsQL questionnaire

T0 : first day of the second cycle of chemotherapy; T1 : 1 month after T0

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Directeur d'études: Anestis Dougkas, Lyfe institute

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

13 décembre 2024

Achèvement primaire (Réel)

13 décembre 2024

Achèvement de l'étude (Estimé)

1 juin 2026

Dates d'inscription aux études

Première soumission

10 mars 2026

Première soumission répondant aux critères de contrôle qualité

2 juin 2026

Première publication (Réel)

8 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

8 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 juin 2026

Dernière vérification

1 mars 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur tests

S'abonner